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OBJECTIVE: Bevacizumab has been widely used as a vascular endothelial growth factor antagonist in the treatment
of retinal vasoproliferative disorders in adults and, more recently, in infants with retinopathy of prematurity.
Recently, it has been proposed that vascular endothelial growth factor acts as a protective factor for neurons and
glial cells, particularly in developing nervous tissue. The purpose of this study was to investigate the effects of
bevacizumab on the developing retinas of juvenile rabbits.
METHODS: Juvenile rabbits received bevacizumab intravitreously in one eye; the other eye acted as an untreated
control. Slit-lamp and fundoscopic examinations were performed both prior to and seven days after treatment. At
the same time, retina samples were analyzed using immunohistochemistry to detect autophagy and apoptosis as
well as proliferation and glial reactivity. Morphometric analyses were performed, and the data were analyzed using
the Mann-Whitney U test.
RESULTS: No clinical abnormalities were observed in either treated or untreated eyes. However, immunohisto-
chemical analyses revealed a reduction in the occurrence of programmed cell death and increases in both
proliferation and reactivity in the bevacizumab-treated group compared with the untreated group.
CONCLUSIONS: Bevacizumab appears to alter programmed cell death patterns and promote gliosis in the
developing retinas of rabbits; therefore, it should be used with caution in developing eyes.
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INTRODUCTION
Bevacizumab (Avastin; Genentech Inc., San Francisco,
California, USA) is a humanized monoclonal antibody that
recognizes all vascular endothelial growth factor (VEGF) (1).
isoforms and is approved by the Food and Drug
Administration for the treatment of metastatic colorectal
cancer (2). Because patients with concomitant age-related
macular degeneration have experienced improved visual
acuity when treated intravenously with bevacizumab, the
possibility of administering the drug intravitreally to treat
neovascularization disorders of the eye without systemic
adverse effects has been investigated (2-4). By early 2006, an
accumulation of compelling functional and anatomical
evidence led to a dramatic increase in the off-label intravitreal
use of bevacizumab as a first-line therapy for exudative age-
related macular degeneration (2). Over the last five years,
intravitreal bevacizumab has been used to treat a rapidly
expanding spectrum of adult retinal diseases (2). based on the
well-established role of VEGF in angiogenesis and vascular
development (5-7). More recently, intravitreous bevacizumab
has been used to treat retinal disease in the developing
retinas of premature infants; by controlling VEGF levels,
bevacizumab inhibits the pathological neovascularization
that is observed in retinopathy of prematurity in infants
receiving oxygen therapy (8,9).
Although it is primarily known for its roles in endothe-
lial cell growth and vascular permeability (6), VEGF has
recently been recognized as a neuroprotective factor in the
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tissues of the central nervous system, including the retina
(7,10). The widespread use of anti-VEGF drugs such as
bevacizumab, combined with the fact that VEGF blockade
can alter the physiological structure of the retina, has led
researchers to evaluate the possible effects of these drugs
on retinal tissue. Although some studies have described
bevacizumab-associated ultrastructural abnormalities in
the retinas of rabbits, mice, and primates (11-13), most
researchers have observed no retinal toxicity in the
developed retinas of adult animals (14-17). One recent in
vivo study evaluated the effect of bevacizumab on the
developing retina; though it described the effect of injection
of the drug into 11- and 25-day-old rabbits (18), no
quantitative analyses of cell death, proliferation or gliosis
were performed. Further in vivo studies in developing
retinas are necessary because, in addition to its significant
effect on angiogenesis and vascular generation during
tissue development, VEGF promotes the proliferation,
differentiation, and survival of retinal glial cells and
neurons, which express VEGF receptors at this develop-
mental stage (1,9). Therefore, VEGF may act as a
neuroprotective and neurotrophic factor in the developing
retina, influencing the growth, differentiation, and survival
of retinal cells (5,7).
The present study was designed to evaluate, both
clinically and histologically, alterations in the developing
retinas of rabbits resulting from intravitreal bevacizumab
administration.
MATERIALS AND METHODS
Animals
All procedures were designed in accordance with the
Association for Research in Vision and Ophthalmology
statement for the use of animals in ophthalmic and vision
research. The study was previously approved by the Ethics
Committee for Animal Research of the Federal University of
Rio de Janeiro. Five juvenile (21-day-old) 500-g male New
Zealand albino rabbits were maintained under a 12/12-h
light/dark cycle with ad libitum access to water and food.
Prior to each experiment, both eyes of each rabbit were
subjected to slit-lamp evaluation, indirect ophthalmoscopy,
and retinal fundus photography to exclude animals with
ocular disorders that might interfere with the results.
Experimental procedures
Prior to experimentation, the rabbits were anesthetized by
intramuscular injection of 25 mg/kg ketamine hydrochlor-
ide and 5 mg/kg xylazine hydrochloride, followed by
instillation of 0.01 g tropicamide in each eye to promote
pupil dilation. After a topical anesthetic (proxymetacaine)
was administered, the left eye of each animal was washed
with 5% povidone iodide and injected intravitreally with
0.03 mL (0.75 mg) of bevacizumab solution (Avastin;
Genentech Inc., San Francisco, California, USA). The
solution was injected into the mid-vitreous cavity, 1.5 mm
posterior to the limbus at the 3-o’clock position, using a 28-
gauge needle attached to a 1.0 mL tuberculin syringe. To
enable observation of the inner structures of the eyes, the
procedure was performed using a surgical microscope. The
untreated right eye of each rabbit was used as a control. The
animals were submitted to a second slit-lamp evaluation
and indirect ophthalmoscopy immediately after bevacizu-
mab administration and before being returned to their
cages. This step was performed to exclude the possibility
that the vehicle or route of administration produced any
alteration in the retina.
Seven days after the injection, the rabbits (then 28 days
old) were evaluated under a slit lamp and submitted to
indirect ophthalmoscopy and retinography to detect inflam-
mation, retinal injury, or cataract formation. The animals
were then anesthetized as described above and euthanized
with an intravenous overdose of 10% potassium chloride.
Histological procedures
The eyes of each animal were enucleated, and sections of
the posterior part of the eye (i.e., the sclera, choroid, and
retina) were obtained by cutting the eyes through the
equator zone. Subsequently, the half-eyes were sectioned
through their vertical diameter, yielding material for
histological analyses that contained the central and periph-
eral retinal areas. The tissue was then fixed in 4%
paraformaldehyde, dehydrated in a graded ethanol series,
cleared in xylene, and embedded in paraffin. Five-micro-
meter sections that were made using a rotary microtome
were mounted on poly-L-lysine-coated slides. The treated-
and control-eye sections were mounted on different slides.
For routine optical microscopy, the sections were stained
with hematoxylin and eosin (HE). For immunohistochem-
ical analysis, the sections were treated with 3% hydrogen
peroxide to inhibit endogenous peroxidases before being
washed with PBS containing 0.2% Triton X-100.
The TUNEL method was used to assess cell death by
autophagy and apoptosis using a rabbit polyclonal anti-
beclin1 primary antibody and an ApopTag peroxidase
detection kit (Chemicon International, Inc., Temecula,
California, USA). To determine whether retinal cells were
proliferating, a mouse monoclonal anti-proliferating cell
nuclear antigen (PCNA) primary antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, California, USA) was used.
At this stage of rabbit development, neurogenesis has
already ceased (19). Therefore, it was assumed that the glial
cells were the only cell type capable of proliferation; this
assumption was confirmed by glial fibrillary acidic protein
detection (GFAP) using a rabbit polyclonal anti-GFAP
primary antibody (Chemicon International, Inc., Temecula,
California, USA), which labeled glial cells.
The first step in the immunohistochemical analysis was
antigen retrieval. First, the slides were either immersed in
0.1 M sodium citrate buffer (pH 6.0) and incubated for
30 min in a steamer pot (for PCNA testing) or immersed in
0.1 M sodium citrate buffer (pH 6.0) and placed in a
microwave at 90 C˚ for 10 min (for beclin1, TUNEL staining,
and glial fibrillary acidic protein [GFAP] testing). The slides
were then washed with cold sodium citrate and PBS before
being treated with 10% bovine serum albumin to block
nonspecific binding of immunoglobulin to the tissues. A
1:100 dilution of a primary antibody against beclin1, PCNA,
or GFAP was then added, and the slides were incubated in a
humid chamber overnight at 4 C˚. Three washes with PBS
containing 0.2% Triton X-100 were performed to terminate
the reaction.
The TUNEL assays were performed according to the
manufacturer’s instructions, with the exception of antigen
retrieval, which included a 10-min incubation step in 0.1 M
sodium citrate buffer (pH 6.0) at 90 C˚.
All immunohistochemical reactions were visualized using
a StreptAB Complex/HRP Duet Kit (Dakocytomation,
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Carpinteria, California, USA) using diamino benzidine
(Chemicon International, Inc., Temecula, California, USA)
as the chromogen. The sections were then counterstained
with hematoxylin, dehydrated in a graded series of
ethanols, cleared in xylene, mounted, and examined using
a light microscope (Zeiss Axioskop 2 Plus; Carl Zeiss,
Baltimore, Maryland, USA).
Quantitative Analysis
Sections containing the central and peripheral retinal
areas from treated and control eyes were evaluated using a
light microscope (63x objective) connected to a digital
camera (Coolpix 990; Nikon, Melville, New York, USA).
This magnification allowed the entire thickness of the retina
to be observed in one field of view. For histomorphometry
analysis, five fields of view for each section of each retina (a
total of 25 fields of view for each of the treated and control
retinas) were chosen at random, and images were recorded
using AxioVision 3.0 software (Carl Zeiss, Baltimore,
Maryland, USA). Uneven illumination and background
were corrected using Adobe Photoshop, version 3.0
(Adobe Systems, San Jose, California, USA).
The cytoplasm staining patterns for beclin1 and GFAP in
both the control and treated retinas, as well as the nuclear
TUNEL staining patterns and PCNA immunohistochemis-
try data, were quantified using Image Pro Plus software
(MediaCybernetics, Bethesda, Maryland, USA). The pre-
sence of brown-stained cytoplasm (for beclin1 and GFAP
analysis) or nuclei (for TUNEL and PCNA analysis) was
marked for subsequent calculation by the software.
The measurements obtained from the two groups (control
and treatment) were compared using the Mann-Whitney U
test. A p-value of less than 0.05 was taken to represent
statistical significance.
RESULTS
Clinical examinations that were performed either imme-
diately following or seven days after intravitreal bevacizu-
mab administration revealed that treatment with the drug
did not cause mechanical injury to the eye tissues or
produce ocular diseases such as conjunctivitis, scleritis,
uveitis, or cataracts (data not shown). Figure 1 shows
examples of fundus photographs of both treated and
untreated animals both prior to and seven days after
treatment, indicating that no abnormalities were observed
in the animals. Routine light microscopy with HE staining
also revealed no abnormalities in any group (Figure 2).
Beclin1 staining was observed in all of the retinal layers
from both groups. However, the cytoplasms of the control
retinas (Figure 3A) were more strongly stained than those
of the treated retinas (Figure 3B). Quantitative analysis
revealed a mean beclin1-positive cytoplasm area of
18.73 mm2 in the control group and 8.22 mm2 in the treated
group, with a significant difference between the groups
(p= 0.0079; Figure 1C).
The TUNEL assay revealed large numbers of apoptotic
nuclei in the control retinas (Figure 3D), particularly in the
ganglion cell and inner nuclear layers; this is in contrast to
the near-complete absence of apoptotic cells in the treated
retinas (Figure 3E). The average number of apoptotic cells
observed was 11.63 for the control group and 3.06 for the
treated group. The difference between the groups was
significant (p= 0.0286; Figure 3F).
Proliferating cell nuclei, detected by immunohistochem-
ical analysis with the anti-PCNA antibody, were particu-
larly numerous in the ganglion cell layers and inner nuclear
layers of the treated retinas (Figure 3H). The mean number
of brown-stained nuclei was higher in the treated group
(21.88) (Figure 3H) than in the control group (8.88)
(Figure 3G); (p= 0.0079; Figure 3I).
Immunohistochemical analysis of GFAP expression
revealed that the retinal cells from both groups were
labeled, though the cells of the treated retinas were more
strongly stained (Figure 3L) than those of the controls
(Figure 3J). Quantitative analysis revealed mean-stained
cytoplasm areas of 14.13 mm2 in the treated retinas and
3.409 mm2 in the controls (p= 0.0079; Figure 3M).
DISCUSSION
The apparent role of VEGF in a spectrum of pathological
neovascular choroid and retinal diseases has led physicians
to use anti-VEGF agents, including bevacizumab, off-label
for the intravitreal treatment of vasoproliferative ocular
disorders. However, the toxicity of bevacizumab to the
retina has become an issue of great concern and has recently
been the subject of intense research (2,10,11,14-17,20-23).
Clinical and histological studies that tested the effect of
bevacizumab on rabbit retinal tissue largely failed to detect
toxicity-induced injury (4,15). However, the safety studies
published thus far have, to our knowledge, only evaluated
adult animals; therefore, they have been limited to assessing
the safety profile of bevacizumab on fully developed retinas
(11,14,16,17,20). During retinal development, VEGF is
expressed by astrocytes in the retinal ganglion cell layer,
Mu¨ller cells and other cells of the inner nuclear layer, and
retinal pigment epithelial cells. Because the VEGF receptor
is expressed in both glial cells and neurons, it has been
suggested that VEGF must play a pivotal role in the
proliferation, differentiation, and survival of the retina (9).
Figure 1 - Fundus photography of a control (A) and treated (C)
eyes before the intravitreal injection of bevacizumab. A repeat
photograph taken seven days after treatment did not reveal
abnormalities in either the control (B) or treated (D) eyes.
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Because of the growing awareness of the neuroprotective
role of VEGF, this study was designed to evaluate alterations
in the developing retinal tissue of rabbits resulting from
intravitreal bevacizumab administration. To this end, we
clinically examined bevacizumab-treated eyes and histologi-
cally characterized them by evaluating programmed cell
death patterns (24,25). and the response of glial cells to VEGF
blockade. In our experiments, one eye of each rabbit received
an intravitreal injection of 0.03 mL bevacizumab. The same
dose is given to preterm babies to treat retinopathy of
prematurity (26), although the therapeutic dosage is still
unknown (27). Because intravitreal treatment with bevacizu-
mab can only be accomplished by injection, the injected eyes
represented the treated group in this study. The contralateral
eyes were left untreated and used as controls. Although
Nomoto et al (28). demonstrated that in rabbits, intravitreous
or subconjunctival bevacizumab injection results in a high
plasma concentration of the drug, the amount of bevacizu-
mab in the contralateral coroid/retina tissue was approxi-
mately 400 times lower than that observed in the injected eye.
Therefore, we believe that the contralateral eye is an adequate
control for the experiment; furthermore, the same approach
has been used in several studies that were published
previously (11,14,16,18). The immunohistochemical changes
we observed between the treatment and control groups
further indicate that the contralateral eye was not affected by
the absorption of bevacizumab.
In the current study, clinical ophthalmic evaluations
performed using a slit-lamp, indirect ophthalmoscopy, and
retinography were used to verify the absence of any
abnormality or pathology either immediately or seven days
after the injection of bevacizumab. This result is consistent
with those obtained in studies using fully developed retinas,
though it does not exclude the possibility of cellular or
molecular damage to the retinal cells (4,17). Therefore, to
assess the possibility of such damage, we performed
histological analyses. Rabbits aged 28 days are considered
juveniles, and their retinas are still undergoing programmed
cell death, which lasts until the 50th postnatal day (19).
During normal eye development, autophagy and apoptosis
help control cell proliferation and maintain the cytoarchitec-
ture and proper function of the retina (29-33). The intense
beclin1 staining, which indicates the presence of autophagy,
and the high number of apoptotic nuclei observed in our
control group confirm that the morphology and physiology
of the retina are still being refined to improve connectivity in
juvenile rabbits (25,32,33). Interestingly, retinas treated with
the anti-VEGF drug bevacizumab exhibited significantly
fewer cells undergoing autophagy and apoptosis than the
control retinas. Considering the importance of programmed
cell death in the developing retina, the blockade of VEGF
with bevacizumab may have caused the observed changes in
the regulation of cell death. Therefore, our results, combined
with the fact that various retinal cells express VEGF and
constitutively activated VEGF receptors (9). during develop-
ment, support the hypothesis that VEGF plays a role in the
control of retinal cell death and differentiation.
Mu¨ller cells, the principal glial cells of the vertebrate retina,
are neuron-supporting cells that span the entire thickness of
the retina and interact closely with all types of neurons.
Mu¨ller cells serve as an anatomical link to sites of molecular
exchange, including retinal blood vessels, the vitreous body
and the subretinal space (34). Mu¨ller cells synthesize and
secrete important signaling molecules, such as trophic
factors, during retinal development (34-36). In response to
any nervous system injury that compromises tissue home-
ostasis, Mu¨ller cells respond with hypertrophy and hyper-
plasia, which characterize gliosis (10,34,37,38). This
phenomenon is reflected immunohistochemically by an
upregulation of the intermediate filament protein GFAP
(34). In this study, the striking increase in the number of
PCNA-positive nuclei in bevacizumab–treated retinas com-
pared with the controls, together with the observed upregu-
lation of GFAP expression, suggest high levels of gliosis. This
finding is suggestive of gliosis because the retinas of juvenile
rabbits, though they are still differentiating, have already
undergone most of the necessary neurogenesis (19). The
intense labeling with the anti-GFAP antibody that was
observed in the treated retinas supports this assumption. In
fact, the idea that increased Mu¨ller cell gliosis occurs upon
treatment with anti-VEGF antibodies has been proposed in
other studies, although these studies used a different
experimental approach (i.e., rat retinal Mu¨ller glial cell
culture) (10). This neuroprotective mechanism is responsible
for the release of neurotrophic factors, including VEGF, in
pathological conditions (10,34). The overexpression of VEGF
during gliosis may explain why it is necessary to administer
recurrent intravitreal injections of bevacizumab to reduce
pathological neovascularization in humans (38).
The histological alterations observed in the developing
rabbit retinas after the intravitreal administration of
bevacizumab represent a novel finding. This preliminary
study used healthy animals and short-term treatments;
therefore, our results do not guarantee that the striking
Figure 2 - Photomicrograph of hematoxylin and eosin-stained control (left) and treated (right) retinas seven days after the experiment.
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Figure 3 - First row: Immunohistochemical staining of beclin1 revealing positive staining in control retinas (A) that is visibly stronger
than that observed in the bevacizumab-treated animals (B). Box plot of the staining area for beclin1 showing a significant difference
(p,0.05) between groups (C). Second row: TUNEL staining showing that the number of apoptotic nuclei (brown) in the control retinas
(D) is significantly higher compared with the bevacizumab-treated retinas. (E). Box plot analysis revealed a significant difference
between groups (p,0.05) (F). Third row: Bevacizumab increases cell proliferation in the retinas of juvenile rabbits. PCNA
immunohistochemical analysis revealed more proliferating cells (brown nuclei) in the bevacizumab-treated retinas (H) than in the
control group (G). The number of proliferating cells (PCNA-positive) in the bevacizumab-treated group was significantly greater
(p,0.05) than that observed in the control group (I). Fourth row: GFAP immunohistochemical analysis revealed stronger staining in the
bevacizumab-treated retinas (L) than in the control retinas (J), indicating that the number of glial cells in the retinas increased after
treatment (p,0.05) (M).
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acute responses observed in the developing retinas will
continue after long-term treatment. However, our results
support the hypothesis that the intravitreal use of this anti-
VEGF agent may not be completely risk-free. It is possible
that the molecular abnormalities observed in the study
could be the result of a combined effect of bevacizumab and
the trauma of injecting the drug into the eye. We believe that
the effect is the result of pharmacological action of
bevacizumab because previous studies that evaluated
saline-injected eyes did not reveal any histological or
electrophysiological abnormalities in the retinas of rabbits
(11,17,18,20). However, even if the abnormalities observed
in the current study were the result of a combination of the
pharmacological effect of bevacizumab and the trauma of
the injection, this would not diminish the importance of the
findings. Because bevacizumab is administered through
intravitreous injections when used as a treatment for retinal
diseases (including those of newborn infants), it is impor-
tant to evaluate the effects of bevacizumab treatment under
the same administration conditions. Therefore, we deter-
mined that the contralateral non-injected eye was the best
possible control to assess the effect of bevacizumab injection
treatment. However, future studies using different routes
for the delivery of bevacizumab to the retina or in vitro
models are necessary for further clarification.
One issue of particular concern is the use of bevacizu-
mab for the treatment of preterm babies suffering from
retinopathy of prematurity, a leading cause of lifelong
visual impairment and blindness in premature babies
(21,39). In these patients, the retina is still undergoing
development, and the potential side effects of anti-VEGF
drugs such as bevacizumab are still unknown (39). To our
knowledge, no clinical trials that have monitored preterm
infants receiving local treatment with bevacizumab have
been completed, and studies of the long-term effects of this
drug on the developing retina are still lacking (40). To
further validate the potential consequences of such
treatment in the developing retinas of premature new-
borns suffering from retinopathy of prematurity, our
findings should be complemented by other investigative
approaches.
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